Ratings Fisher & Paykel Healthcare Corporation Limited Deutsche Boerse AG
Equities
FPLB
NZFAPE0001S2
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.3 EUR | -2.40% | +2.45% | +26.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Sales forecast by analysts have been recently revised upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 50.65 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.52% | 10.7B | - | ||
-2.34% | 187B | C+ | ||
+0.92% | 110B | C | ||
-1.77% | 69.54B | A | ||
+14.21% | 46.37B | B- | ||
-6.06% | 46.05B | B- | ||
+7.97% | 42.54B | B+ | ||
+19.03% | 30.72B | B | ||
+17.70% | 25.62B | A- | ||
-7.25% | 23.32B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- FPH Stock
- FPLB Stock
- Ratings Fisher & Paykel Healthcare Corporation Limited